$-1.58 EPS Expected for Novelion Therapeutics Inc. (NVLN)

February 27, 2018 - By Dolores Ford

 $ 1.58 EPS Expected for Novelion Therapeutics Inc. (NVLN)

Analysts expect Novelion Therapeutics Inc. (NASDAQ:NVLN) to report $-1.58 EPS on March, 21.They anticipate $0.18 EPS change or 10.23 % from last quarter’s $-1.76 EPS. After having $-0.89 EPS previously, Novelion Therapeutics Inc.’s analysts see 77.53 % EPS growth. The stock decreased 0.86% or $0.039 during the last trading session, reaching $4.491. About 5,722 shares traded. Novelion Therapeutics Inc. (NASDAQ:NVLN) has risen 31.51% since February 27, 2017 and is uptrending. It has outperformed by 14.81% the S&P500.

Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases. The company has market cap of $83.77 million. The Company’s product portfolio includes MYALEPT , a recombinant analogue of human leptin, indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the brand names of JUXTAPID and LOJUXTA. It currently has negative earnings. The company's orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, in late stage development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes.

More notable recent Novelion Therapeutics Inc. (NASDAQ:NVLN) news were published by: Seekingalpha.com which released: “Novelion Therapeutics’ (NVLN) CEO Mary Szela on Bloom Burton & Co. Healthcare …” on May 02, 2017, also Globenewswire.com with their article: “Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey …” published on October 31, 2017, Seekingalpha.com published: “Novelion Therapeutics’ (NVLN) CEO Mary Szela on Q1 2017 Results – Earnings …” on May 14, 2017. More interesting news about Novelion Therapeutics Inc. (NASDAQ:NVLN) were released by: Marketwatch.com and their article: “Novelion Therapeutics Inc.” published on February 07, 2017 as well as Globenewswire.com‘s news article titled: “Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes” with publication date: June 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: